Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

NCT00791518 · View on ClinicalTrials.gov ↗

Study Summary

A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.

Interventions

  • DRUG No intervention

Study Locations (20)

Florida

  • GSK Investigational Site — Cocoa
  • GSK Investigational Site — DeLand
  • GSK Investigational Site — Largo
  • GSK Investigational Site — Miami
  • GSK Investigational Site — Miami
  • GSK Investigational Site — Naranja
  • GSK Investigational Site — South Miami
  • GSK Investigational Site — Tamarac
  • GSK Investigational Site — Tampa

California

  • GSK Investigational Site — National City
  • GSK Investigational Site — Rancho Mirage
  • GSK Investigational Site — Riverside
  • GSK Investigational Site — Santa Ana
  • GSK Investigational Site — Walnut Creek

Colorado

  • GSK Investigational Site — Colorado Springs
  • GSK Investigational Site — Colorado Springs

Alabama

  • GSK Investigational Site — Birmingham

Arizona

  • GSK Investigational Site — Tucson

Arkansas

  • GSK Investigational Site — Little Rock

Connecticut

  • GSK Investigational Site — Stamford

Trial Details

FieldValue
Enrollment Target 1,084 participants
Start Date 2008-12
Est. Completion 2009-05

Sponsor

GlaxoSmithKline

558 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00791518

The ClinicalTrials.gov registry entry for NCT00791518 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,084 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 558 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention — of which No intervention is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00791518 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00791518 about?

NCT00791518 is a clinical study titled "Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy". A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.

What is the current status of trial NCT00791518?

This trial is currently completed. The enrollment target is 1,084 participants. The study started on 2008-12. Estimated completion is 2009-05.

What conditions does trial NCT00791518 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00791518?

The interventions under investigation include: No intervention (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00791518?

This trial is sponsored by GlaxoSmithKline, which has 558 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00791518 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial